SCHEMBL6511530

SCHEMBL6511530

COC(=O)c1cc(Cl)ccc1NC(=O)CC(=O)N(C)OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.48
KMT2A Q03164 6/20 0.47
MEN1 O00255 5/20 0.47
GAA P10253 3/20 0.45
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 4/20 0.44
ABL1 P00519 1/20 0.43
HSD17B10 Q99714 2/20 0.43
PKM P14618 1/20 0.43
RAB9A P51151 1/20 0.43
LMNA P02545 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 2/20 0.42
POLB P06746 1/20 0.42
USP2 O75604 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6510154 0.82 KMT2A (0.63) RXFP1KMT2AMEN1GAAKDM4E
SCHEMBL30044907 0.82 KMT2A (0.63) RXFP1KMT2AMEN1GAAKDM4E
SCHEMBL417874 0.81 RXFP1 (0.54) RXFP1KMT2AMEN1GAAKDM4E
SCHEMBL30556513 0.80 RXFP1 (0.53) RXFP1KMT2AMEN1GAAKDM4E
SCHEMBL9674267 0.80 ALDH1A1 (0.65) RXFP1KMT2AMEN1GAAKDM4E
SCHEMBL7931410 0.80 RXFP1 (0.53) RXFP1KMT2AMEN1GAAKDM4E
SCHEMBL7125633 0.79 ALDH1A1 (0.62) RXFP1KMT2AMEN1GAAKDM4E
SCHEMBL1796237 0.79 ALDH1A1 (0.54) RXFP1KMT2AMEN1GAAKDM4E
SCHEMBL10813601 0.78 ABL1 (0.50) RXFP1KMT2AMEN1GAAKDM4E
SCHEMBL6511527 0.78 KMT2A (0.51) RXFP1KMT2AMEN1GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050245563-A1 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-03 US disclosed
WO-2005028474-A2 PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245563-A1 Chk-1 inhibitors CHKA, CHKB, CHEK1 RXFP1 3989/4885KMT2A 1919/4885MEN1 1973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.